Seres Therapeutics Inc (NASDAQ:MCRB) Expected to Announce Earnings of -$0.30 Per Share

Wall Street brokerages expect Seres Therapeutics Inc (NASDAQ:MCRB) to announce ($0.30) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Seres Therapeutics’ earnings. The lowest EPS estimate is ($0.45) and the highest is ($0.21). Seres Therapeutics posted earnings per share of ($0.54) during the same quarter last year, which would suggest a positive year over year growth rate of 44.4%. The firm is expected to report its next quarterly earnings report on Thursday, November 14th.

On average, analysts expect that Seres Therapeutics will report full-year earnings of ($1.55) per share for the current fiscal year, with EPS estimates ranging from ($1.93) to ($1.16). For the next year, analysts expect that the company will post earnings of ($1.08) per share, with EPS estimates ranging from ($1.66) to ($0.77). Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that follow Seres Therapeutics.

Seres Therapeutics (NASDAQ:MCRB) last announced its earnings results on Tuesday, August 6th. The biotechnology company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.17. The company had revenue of $12.53 million for the quarter, compared to analyst estimates of $10.29 million.

A number of research analysts have weighed in on MCRB shares. ValuEngine raised Seres Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. BidaskClub lowered Seres Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, May 3rd. Zacks Investment Research raised Seres Therapeutics from a “hold” rating to a “buy” rating and set a $3.50 price target on the stock in a research note on Thursday, July 4th. HC Wainwright reissued a “buy” rating and set a $8.00 price target on shares of Seres Therapeutics in a research note on Friday, May 3rd. Finally, Jefferies Financial Group reduced their price target on Seres Therapeutics from $6.00 to $4.00 and set a “hold” rating on the stock in a research note on Monday, July 1st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the stock. Seres Therapeutics has an average rating of “Buy” and an average price target of $10.25.

In other news, Director Noubar Afeyan bought 8,888,888 shares of the business’s stock in a transaction that occurred on Tuesday, June 18th. The shares were acquired at an average cost of $2.25 per share, with a total value of $19,999,998.00. Following the transaction, the director now owns 15,141 shares of the company’s stock, valued at approximately $34,067.25. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 37.00% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of the stock. Perceptive Advisors LLC bought a new position in Seres Therapeutics in the second quarter worth about $8,050,000. Walleye Trading Advisors LLC bought a new position in Seres Therapeutics in the second quarter worth about $91,000. Walleye Trading LLC bought a new position in Seres Therapeutics in the second quarter worth about $87,000. CVI Holdings LLC bought a new position in Seres Therapeutics in the second quarter worth about $727,000. Finally, Jane Street Group LLC bought a new position in Seres Therapeutics in the second quarter worth about $369,000.

NASDAQ:MCRB traded up $0.12 during trading hours on Monday, reaching $2.97. 265,800 shares of the company traded hands, compared to its average volume of 290,097. The firm’s 50-day moving average is $2.86 and its 200-day moving average is $4.72. The stock has a market cap of $207.63 million, a P/E ratio of -1.22 and a beta of 2.03. Seres Therapeutics has a 1-year low of $2.02 and a 1-year high of $9.26.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome. The company's advanced program is the SER-109, which is in Phase III clinical development for reducing recurrent clostridium difficile infection (CDI).

Read More: How to Profit and Limit Losses With Stop Orders

Get a free copy of the Zacks research report on Seres Therapeutics (MCRB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.